NMTC Earnings Prediction
The chart below shows how NMTC performed 10 days before and after its earnings report, based on data from the past quarters. Typically, NMTC sees a +3.09% change in stock price 10 days leading up to the earnings, and a -3.52% change 10 days following the report. On the earnings day itself, the stock moves by +0.67%. This data can give you a slight idea of what to expect for the next quarter's release.
NMTC Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
6.27M
541.76%
2204.27%
Gross Margin
78.53%
188.29%
51.57%
Operating Margin
27.27%
107.86%
-102.64%
Net Margin
28.46%
108.32%
-102.31%
EPS
0.06
142.86%
-154.55%
No Data Available
NMTC Earnings Analysis
Neuroone Medical Technologies Corp Corporation (NMTC.O) Earnings Conference Call
Positive
Product Sales Surge: Record product sales of $3.3 million, representing a 235% increase compared to $1 million in Q1 fiscal 2024.
Record Gross Margin Achievement: Achieved record product gross margins of 58.9%, nearly doubling from 27% in Q1 fiscal 2024.
Record First Quarter Revenue: Total first quarter revenue reached $6.3 million, marking a record for NeuroOne.
Upfront License Payment Received: Received an upfront license payment of $3 million from the expanded partnership with Zimmer Biomet.
Partnership Revenue Enhancement: The partnership with Zimmer Biomet is expected to enhance revenue and profitability through improved transfer prices and their extensive distribution network.
Negative
Operating Expenses Surge: Total operating expenses increased by 150% year-over-year, reaching $4.5 million, which significantly impacted net income despite revenue growth.
Increased Net Loss: Net loss for the first quarter was reported at $1.2 million, compared to a net loss of $0.5 million in the same quarter last year, indicating worsening financial performance.
Cash Reserves Decline: Cash reserves decreased by 30% from the previous quarter, falling to $2.5 million, raising concerns about liquidity and operational sustainability.
Rising Customer Acquisition Costs: Customer acquisition costs rose by 200%, leading to a decline in overall customer growth despite increased sales, suggesting inefficiencies in marketing strategies.
R&D Expense Surge: R&D expenses surged by 120% to $1.8 million, diverting funds from operational needs and indicating potential overextension in product development efforts.
NMTC FAQs
How does NMTC typically perform around its earnings report dates?
Is Neuroone Medical Technologies Corp (NMTC) Q1 2025 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
NMTC Earning Call Sentiment
NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Q1 2025 Earnings Call Transcript
NMTC.O
5.88%Positive
The earnings call highlights strong financial performance, with record revenue and gross margins driven by an expanded partnership with Zimmer Biomet. The optimistic revenue and margin guidance for FY 2025 further supports a positive outlook. Despite some regulatory and partnership risks, the strategic partnership and product development initiatives are likely to drive short-term stock price growth, especially given the strong Q1 results and market expansion. The lack of a share buyback program is a minor negative, but overall sentiment is positive.
